Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Praxis Precision Medicines Inc PRAX

Healthcare Biotechnology
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company’s platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and... see more

Current News (NDAQ:PRAX)

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 3 days ago

Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

GlobeNewswire January 13, 2026

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

GlobeNewswire January 12, 2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 9, 2026

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

GlobeNewswire January 8, 2026

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

GlobeNewswire January 6, 2026

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

GlobeNewswire January 6, 2026

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

GlobeNewswire December 29, 2025

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

GlobeNewswire December 11, 2025
View More News ››

Opinion & Analysis (NDAQ:PRAX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:PRAX)

RE:Buy buddy buy because it's taking off this morning.

got to had it to you cool. how do you find these.  consider me impressed. 
longball44 - December 5, 2025

Buy buddy buy because it's taking off this morning.

Otherwise FOMO for you fellas out there today anyway,so good luck to all of you guys
coolfooldumbguy - December 5, 2025

Buy buddy buy because it's taking off this morning.

Otherwise FOMO
coolfooldumbguy - October 16, 2025

Praxis Precision Medicines, Inc. (NASDAQ:PRAX): A Promising

http://beyondspx.com/2024/08/01/praxis-precision-medicines-inc-nasdaqprax-a-promising-biopharmaceutical-company-translating-genetic...
MikeTester - August 1, 2024
View more Bullboard ››

Blue Sky Uranium Corp.

Blue Sky Uranium Corp.

Blue Sky Uranium Corp., a junior uranium exploration company, engages in the acquisition, exploration, and evaluation of ...
View More »

Podcasts